tiprankstipranks
In this article:
Blurbs

United Therapeutics (UTHR) Received its Third Buy in a Row

In this article:
In this article:

After J.P. Morgan and Ladenburg Thalmann & Co. gave United Therapeutics (NASDAQ: UTHR) a Buy rating last month, the company received another Buy, this time from Jefferies. Analyst Eun Yang maintained a Buy rating on United Therapeutics today and set a price target of $223.00. The company’s shares closed last Wednesday at $175.35.

According to TipRanks.com, Yang is a 4-star analyst with an average return of 4.6% and a 47.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as Taysha Gene Therapies, Blueprint Medicines, and Keros Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for United Therapeutics with a $235.83 average price target, implying a 41.6% upside from current levels. In a report issued on February 25, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $203.00 price target.

See the top stocks recommended by analysts >>

United Therapeutics’ market cap is currently $7.91B and has a P/E ratio of 17.49.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Read More on UTHR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed